Sentient’s inaugural CEO Oliver Yates who recently moved into a new role focusing on more complex projects has agreed with the board to end his tenure with Sentient. Oliver has more than 30 years’ experience in investment management and clean energy and, as Sentient’s inaugural CEO was fundamental in establishing and growing the business. The Sentient Board and team acknowledge and thank Oliver for his contribution to the foundational year of Sentient.
“Its been a pleasure to build a team of passionate staff and I look forward to collaborating with them on future projects where possible. Together regardless of where we are all working we are in the fight of our lives and that of our children’s lives and I highly respect and appreciate every individual that is doing all they can to tackle the environmental crisis we all face” said Oliver.
Darren Dawson will be the Interim CEO and will remain in the role until a permanent CEO is appointed, with that search already underway. Darren has been the CFO of Sentient since April 2022. Darren has over 20 years of banking and financial services experience. He has worked in a broad range of roles that have included finance, risk and customer facing responsibilities with a specific a focus on Treasury and financial markets. He enjoys working in a role where impact investment contributes solutions to environmental and social issues. Prior to Sentient, Darren was the Head of Impact Finance at Bank Australia where he was responsible for the origination of impact lending and investment assets predominantly for clean energy transition, community and disability housing clients.
Darren is a Chartered Accountant and a Graduate of the Australian Institute of Company Directors (GAICD). He has a Master of Science from the University of Edinburgh, a Bachelor of Arts/Commerce from Monash University and a Graduate Diploma of Financial Planning. He is a Director of the Melanoma and Skin Cancer Advocacy Network, a not for profit working to improve care and outcomes for those effected by a serious skin cancer diagnosis.
The board and management of Sentient are completing a review of the business’ foundational year, and agreeing on market and capability needs going forward.